Bausch Health Reports Q2 Earnings Miss, Revenue Beats Expectations

Bausch Health Companies reported Q2 earnings of 90 cents per share, missing the Zacks Consensus Estimate of 97 cents. Total revenues were $2.53 billion, up 5% YoY and beating the Zacks Consensus Estimate of $2.5 billion. However, shares of the company declined 6.3% after the earnings release.

Bausch Health Companies Inc. (BHC) reported mixed second-quarter (Q2) results for 2025, with adjusted earnings per share (EPS) of 90 cents missing the Zacks Consensus Estimate of 97 cents. However, total revenues reached $2.53 billion, a 5% year-over-year (YoY) increase and exceeding the Zacks Consensus Estimate of $2.5 billion. Despite the positive revenue growth, BHC's shares fell 6.3% following the earnings release [1].

The company's Q2 performance was driven by strong growth in several segments. Salix, which focuses on gastrointestinal (GI) disorders, reported revenues of $627 million, up 12% YoY, with key products like Xifaxan and Trulance showing significant growth. International revenues totaled $278 million, up 1% YoY, led by growth in the EMEA region. Solta Medical, a medical device company, saw revenues of $128 million, up 25% YoY, primarily driven by volume expansion in South Korea. Bausch + Lomb, the company's vision care segment, reported revenues of $1.3 billion, up 5% YoY, with strong growth in the vision care segment [1].

However, Diversified Products, which includes neurology, dentistry, generics, and dermatology businesses, saw revenues of $219 million, down 13% from the year-ago level. This segment was negatively impacted by fluctuations in demand for Cardizem and lower net realized pricing for mature non-promoted brands in the dermatology business [1].

BHC's debt obligations continue to be a significant concern, with debt of $21.7 billion and a cash balance of $1.7 billion as of June 2025. The company announced an upcoming repayment of approximately $900 million of debt. Additionally, BHC is conducting an internal review on pipeline candidate amiselimod and submitted its application seeking approval of Cabtreo to the EMA [1].

Despite the mixed results, BHC carries a Zacks Rank #2 (Buy), indicating a positive outlook. Investors should closely monitor the company's debt situation and pipeline developments for potential catalysts in the coming quarters [1].

References:
[1] https://finance.yahoo.com/news/bausch-health-stock-falls-q2-144800943.html